{"id":"https://openalex.org/W2808949210","doi":"https://doi.org/10.2337/db18-2364-pub","title":"The Safety of Linagliptin vs. Other Antidiabetic Agents with Regard to the Risk of Heart Failure Hospitalization in Routine Care in the U.S.","display_name":"The Safety of Linagliptin vs. Other Antidiabetic Agents with Regard to the Risk of Heart Failure Hospitalization in Routine Care in the U.S.","publication_year":2018,"publication_date":"2018-06-22","ids":{"openalex":"https://openalex.org/W2808949210","doi":"https://doi.org/10.2337/db18-2364-pub","mag":"2808949210"},"language":"en","primary_location":{"id":"doi:10.2337/db18-2364-pub","doi":"https://doi.org/10.2337/db18-2364-pub","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db18-2364-pub","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044474781","display_name":"Elisabetta Patorno","orcid":"https://orcid.org/0000-0002-8809-9898","observed_orcids":["https://orcid.org/0000-0002-8809-9898"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ELISABETTA PATORNO","raw_affiliation_strings":["Boston, MA, Ridgefield, CT, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ridgefield, CT, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089109829","display_name":"Mufaddal Mahesri","orcid":"https://orcid.org/0000-0002-6684-2337","observed_orcids":["https://orcid.org/0000-0002-6684-2337"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MUFADDAL MAHESRI","raw_affiliation_strings":["Boston, MA, Ridgefield, CT, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ridgefield, CT, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065580650","display_name":"Chandrasekar Gopalakrishnan","orcid":"https://orcid.org/0000-0003-2424-2453","observed_orcids":["https://orcid.org/0000-0003-2424-2453"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"CHANDRASEKAR GOPALAKRISHNAN","raw_affiliation_strings":["Boston, MA, Ridgefield, CT, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ridgefield, CT, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036238582","display_name":"Kimberly Goodnow Brodovicz","orcid":"https://orcid.org/0000-0001-8275-1649","observed_orcids":["https://orcid.org/0000-0001-8275-1649"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"KIMBERLY BRODOVICZ","raw_affiliation_strings":["Boston, MA, Ridgefield, CT, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ridgefield, CT, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111677112","display_name":"Andrea Meyers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ANDREA MEYERS","raw_affiliation_strings":["Boston, MA, Ridgefield, CT, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ridgefield, CT, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110393298","display_name":"Dorothee B. Bartels","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"DOROTHEE BARTELS","raw_affiliation_strings":["Boston, MA, Ridgefield, CT, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ridgefield, CT, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004416630","display_name":"Sebastian Schneewei\u00df","orcid":"https://orcid.org/0000-0003-2575-467X","observed_orcids":["https://orcid.org/0000-0003-2575-467X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"SEBASTIAN SCHNEEWEISS","raw_affiliation_strings":["Boston, MA, Ridgefield, CT, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Ridgefield, CT, Ingelheim, Germany","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.08060403,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"67","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.006899999920278788,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10821","display_name":"Cardiovascular Function and Risk Factors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/linagliptin","display_name":"linagliptin","score":1.0},{"id":"https://openalex.org/keywords/heart-failure-hospitalization","display_name":"heart failure hospitalization","score":0.9660000205039978},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9800000190734863},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/sitagliptin","display_name":"sitagliptin","score":0.9710000157356262},{"id":"https://openalex.org/keywords/saxagliptin","display_name":"saxagliptin","score":1.0},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":1.0},{"id":"https://openalex.org/keywords/antidiabetic-drugs","display_name":"antidiabetic drugs","score":0.8100000023841858},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8510000109672546},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.6729999780654907},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.765999972820282},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.597000002861023},{"id":"https://openalex.org/keywords/health-insurance-claims-data","display_name":"health insurance claims data","score":0.7390000224113464},{"id":"https://openalex.org/keywords/fixed-effects-meta-analysis","display_name":"fixed-effects meta-analysis","score":0.5389999747276306}],"concepts":[{"id":"https://openalex.org/C2780031085","wikidata":"https://www.wikidata.org/wiki/Q909745","display_name":"Linagliptin","level":4,"score":0.9852157831192017},{"id":"https://openalex.org/C2780282729","wikidata":"https://www.wikidata.org/wiki/Q3121121","display_name":"Saxagliptin","level":5,"score":0.966342568397522},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8589341044425964},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.8478556871414185},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6086551547050476},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5870854258537292},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.5638435482978821},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.47346654534339905},{"id":"https://openalex.org/C17923572","wikidata":"https://www.wikidata.org/wiki/Q7250160","display_name":"Propensity score matching","level":2,"score":0.4716213047504425},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.43704715371131897},{"id":"https://openalex.org/C120195587","wikidata":"https://www.wikidata.org/wiki/Q2138790","display_name":"Absolute risk reduction","level":3,"score":0.4245885908603668},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.3894508481025696},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.18208125233650208},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.15143802762031555},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db18-2364-pub","doi":"https://doi.org/10.2337/db18-2364-pub","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db18-2364-pub","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2342633464","https://openalex.org/W2973090108","https://openalex.org/W2763872313","https://openalex.org/W103558615","https://openalex.org/W2081294423","https://openalex.org/W4399691212","https://openalex.org/W2467533047","https://openalex.org/W2900102850","https://openalex.org/W2756082893","https://openalex.org/W2216127328"],"abstract_inverted_index":{"The":[0],"safety":[1],"of":[2,9,29,35,41,92,129,163],"linagliptin":[3,42,208],"with":[4,17,38,132,186,190],"regard":[5],"to":[6,152],"the":[7,33,39,127],"risk":[8,34,128,156,182,199],"hospitalization":[10],"for":[11],"heart":[12],"failure":[13],"(HHF)":[14],"in":[15,25,94,126,160,180],"patients":[16,63,165],"type":[18],"2":[19],"diabetes":[20],"mellitus":[21],"(T2DM)":[22],"as":[23],"treated":[24],"routine":[26],"care":[27],"remains":[28],"interest.":[30],"We":[31,87,107],"compared":[32,131],"HHF":[36,93,130,181,198],"associated":[37],"initiation":[40],"vs.":[43,200],"other":[44],"antidiabetic":[45],"agents.":[46],"In":[47,150],"two":[48],"large":[49],"commercial":[50],"U.S.":[51,280],"health":[52],"insurance":[53],"datasets":[54],"(Optum":[55],"Clinformatics":[56],"and":[57,74,76,282],"Truven":[58],"MarketScan),":[59],"we":[60,174],"identified":[61],"T2DM":[62,164],"who":[64],"initiated":[65],"linagliptin,":[66],"sitagliptin,":[67],"saxagliptin,":[68],"or":[69,84,144],"sulfonylureas":[70],"(SU)":[71],"between":[72,183],"5/2011":[73],"9/2015":[75],"had":[77,122],"no":[78,123],"previous":[79],"Heart":[80],"Failure":[81],"(HF)":[82],"history":[83],"HF":[85,167],"treatment.":[86],"estimated":[88],"hazard":[89],"ratios":[90],"(HR)":[91],"3":[95],"separate":[96],"propensity":[97],"score":[98],"matched":[99],"cohorts":[100],"that":[101],"balanced":[102],"over":[103],"130":[104],"baseline":[105],"characteristics.":[106],"combined":[108],"HRs":[109],"via":[110],"a":[111,161,178,196],"fixed-effects":[112],"meta-analysis.":[113],"Mean":[114],"follow-up":[115],"was":[116],"nearly":[117],"8":[118],"months.":[119],"Linagliptin":[120],"initiators":[121],"significant":[124],"difference":[125,179],"sitagliptin":[133],"(HR=":[134,140,146],"0.83":[135],"[95%":[136],"CI=0.58,":[137],"1.20]),":[138],"saxagliptin":[139],"1.13":[141],"[0.74,":[142],"1.71]),":[143],"SU":[145],"0.71,":[147],"[0.46,":[148],"1.10]).":[149],"contrast":[151],"high":[153],"cardiovascular":[154],"(CV)":[155],"clinical":[157],"trial":[158],"populations,":[159],"population":[162],"without":[166],"history,":[168],"aged":[169],"57":[170],"years":[171],"on":[172,220],"average,":[173],"did":[175],"not":[176],"find":[177],"DPP-4":[184],"inhibitors":[185],"sufficient":[187],"certainty.":[188],"Consistent":[189],"prior":[191],"studies,":[192],"there":[193],"may":[194],"be":[195],"reduced":[197],"SU;":[201],"further":[202],"evidence":[203],"is":[204],"expected":[205],"from":[206],"ongoing":[207],"CV":[209],"outcomes":[210],"trials.":[211],"Disclosure":[212],"E.":[213],"Patorno:":[214],"Research":[215,270,287],"Support;":[216,271],"Self;":[217,224,239,247,255,262,267,272],"National":[218],"Institute":[219],"Aging.":[221],"Other":[222,265],"Relationship;":[223,266],"Boehringer":[225,240,248,256,277],"Ingelheim":[226,241,249,257,278],"GmbH,":[227,279],"GlaxoSmithKline":[228],"plc..":[229],"M.":[230],"Mahesri:":[231],"None.":[232,235],"C.":[233],"Gopalakrishnan:":[234],"K.":[236],"Brodovicz:":[237],"Employee;":[238,246,254],"Pharmaceuticals,":[242,250],"Inc.":[243,251],"A.":[244],"Meyers:":[245],"D.":[252],"Bartels:":[253],"GmbH.":[258],"S.":[259],"Schneeweiss:":[260],"Consultant;":[261],"WHISCON,":[263],"LLC.":[264],"Aetion,":[268],"Inc..":[269],"Genentech,":[273],"Inc.,":[274],"Bayer":[275],"AG,":[276],"Food":[281],"Drug":[283],"Administration,":[284],"Patient-Centered":[285],"Outcomes":[286],"Institute.":[288]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2018-06-29T00:00:00"}